(44.192.70.216) 您好!臺灣時間:2021/05/09 18:12
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:陳俊仁
研究生(外文):Chen Chun Jen
論文名稱:酸類緣物對於人類前骨髓性血癌細胞(HL-60cells)
論文名稱(外文):Effect of Indole-3-acetic acid Analogs on Differentiation
指導教授:郭盛助 教 授賴建銘賴建銘引用關係
指導教授(外文):Kuo Sheng ChuLai Jem Min
學位類別:碩士
校院名稱:中國醫藥學院
系所名稱:藥物化學研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2001
畢業學年度:89
語文別:中文
論文頁數:80
中文關鍵詞:細胞分化劑 -3-醋酸類緣物全反式維甲酸人類前骨髓性白血病細胞週期
外文關鍵詞:cell differentiation agentsIndole-3-acetic acid ( IAA ) analogsall-trans retinoic acid ( ATRA )acute promyelocytic leukemia ( APL )cell cycleHL-60 cellNBT
相關次數:
  • 被引用被引用:1
  • 點閱點閱:468
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
為了尋求新型的細胞分化劑,著者針對一系列-3-醋酸
( IAA ) 類緣物進行分化作用與抑制增殖作用之篩選工作。發現化合物IAA-Ile及IAA-Phe其二者對促進全反式維甲酸分化活性之效果最為顯著。於是進一步地以其對HL-60細胞週期之影響及細胞表面抗原表現來探討其初步作用機轉。
當化合物IAA-Ile及IAA-Phe與全反式維甲酸併用時,其對細胞週期及細胞表面抗原表現影響的結果顯示與全反式維甲酸於誘導細胞分化時產生的結果相似。綜合本研究結果:化合物IAA-Ile及IAA-Phe併用全反式維甲酸使用於人類前骨髓性白血病的分化療法上應有不錯的助益。
In order to develop the novel cell differentiation agents, a series of Indole-3-acetic acid ( IAA ) analogs were screened for their differentiation and antiproliferation activities of HL-60 cells. Compounds, IAA-Ile and IAA-Phe were found to be the most effective to potentiate the induction of differentiation by all-trans retinoic acid ( ATRA ). Therefore the further studies were carried out to evaluate their effects on the cell cycle and cell surface antigen expression of HL-60 cells.
When combined with ATRA, compounds IAA-Ile and IAA-Phe were found to affect the cell cycle and cell surface antigen expression in the same manner as ATRA. This finding suggest that IAA-Ile and IAA-Phe when administered together with ATRA, may have beneficial therapeutic effects in the treatment of acute promyelocytic leukemia ( APL ).
表目錄………….…………………………………………………III
圖目錄………………………………………………………………IV
中文摘要……………………………………………………………1
英文摘要……………………………………………………………2
第 一 章 緒論……………………………………………………3
第一節白血病( Leukemia )的治療………………………... 3
第二節分化療法………………………………………………6
第三節All-trans Retinoic acid ( ATRA ) 臨床使用的
現況…….....................................11
第四節 Indole-3-acetic acid 在癌症治療上的新展望…..14
第五節 細胞週期與細胞分化的關係………………………...16
第六節 細胞分化的表面抗原( cell surface antigen )
表現………...................................19
第 二 章 研究動機……………………………………………..22
第 三 章 實驗材料和方法……………………………………..24
第一節實驗材料和儀器……………………………………...24
第二節人類前骨髓性白血病細胞( HL-60 cells )的培養..28
第三節Indole-3-acetylamino acid derivatives及
Indoleacetamide derivatives與加藥處理( treatment )
…………………….............................28
第四節Indole-3-acetylamino acid derivatives及
Indoleacetamide derivatives對HL-60 cells分化作用及細胞
增殖之影響...................................29
第五節Indole-3-acetylamino acid derivatives及
Indoleacetamide derivatives對血癌細胞( HL-60 cells )細
胞週期( Cell cycle )之影響…………………….. 32
第六節Indole-3-acetylamino acid derivatives及
Indoleacetamide derivatives對HL-60 cells表面抗原表現之
影響………...................................33
第 四 章 實驗結果………………………………………………34
第一節 Indole-3-acetylamino acid衍生物及Indoleacetamide衍生
物對HL-60細胞分化活性與增殖抑制效果之初步篩選34
( I ) Indole-3-acetylamino acid衍生物及Indoleacetamide衍
生物對HL-60細胞分化的影響……………………... 35
( II ) Indole-3-acetylamino acid衍生物及Indoleacetamide衍生
物對HL-60細胞增殖的影響..................36
第二節 IAA-Ile及IAA-Phe對HL-60細胞之初步分化作用機轉.37
( I ) IAA-Ile及IAA-Phe對HL-60細胞分化的影響………. 37
( II ) IAA-Ile及IAA-Phe對HL-60細胞增殖及細胞週期的
影響…………………………………………….......39
( III )IAA-Ile及IAA-Phe對HL-60 細胞表面抗原表現的影響
………………………………………………………...41
第 五 章 討論…………………………………………………… 65
第 六 章 結論…………………………………………………… 69
參考文獻 ………………………………………………………. 71
1.Peter, H.; Wiernik. et. al. Neoplastic diseases of the Blood,
3rd ed. New York : Churchill Livingstone, 1996. Chapter 13,
P191.
2.Miller, B.A.; Kolonel, L. N.; Bernstein, L.; Young, Jr. J.
L.; Swanson, G. M.; West, D.; Key, C. R.; Liff, J. M.;
Glover, C. S.; Alexander, G. A. Racial/Ethnic Patterns of
Cancer in the United States 1988-1992, National Cancer
Institute. NIH Pub. No. 96-4104. Bethesda, MD, 1996.
3.Sandler, D. P.; Ross, J. A. Epidemiology of acute leukemia in
children and adults. [Review] Semin. Oncol. 24(1): 3-16, 1997.
4.Vogel, V. G.; Fisher, R. E. Epidemiology and etiology of
leukemia. [Review] Curr. Opin. Oncol. 5(1): 26-34, 1993.
5.Kakizuka, A.; Miller, W. H; Jr. Umesono, K. ; Warrell, R. P;
Jr. Frankel, S. R.;Murty, V. V.; Dmitrovsky, E.; Evans, R. M.
Chromosomal translocation t(15;17) in human acute
promyelocytic leukemia fuses RAR alpha with a novel putative
transcription factor, PML. Cell, 66(4): 663-674, 1991.
6.Ichikawa, Y. Differentiation of a cell line of myeloid
leukemia. J. Cell Physiol. 74: 223-234, 1969.
7.Friend, C.; Scher, W.; Holland, J. G.; Sato, T. Hemoglobin
synthesis in murine virus-induced leukemic cells in vitro:
stimulation of erythroid differentiation by dimethyl
sulfoxide. Proc. Natl. Acad. Sci. USA. 68(2): 378-82, 1971.
8.Collins, S. J.; Ruscetti, F. W.; Gallagher, R. E.; Gallo, R.
C. Terminal differentiation of human promyelocytic leukemia
cells induced by dimethyl sulfoxide and other polar
compounds. Proc. Natl. Acad. Sci. USA. 75(5): 2458-2462, 1978.
9.Gallagher, R.; Collins, S.; Trujillo, J.; McCredie, K.;
Ahearn, M.; Tsai, S.; Metzgar, R.; Aulakh, G.; Ting, R.;
Ruscetti, F.; Gallo, R. Characterization of the continuous,
differentiating myeloid cell line (HL-60) from a patient with
acute promyelocytic leukemia. Blood, 54(3): 713-733, 1979.
10.Breitman, T. R.; Selonick, S. E.; Collins, S. J. Induction
of differentiation of the human promyelocytic leukemia cell
line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA. 77
(5): 2936-2940, 1980.
11.Breitman, T. R.; Collins, S. J.; Keene, B. R. Terminal
differentiation of human promyelocytic leukemic cells in
primary culture in response to retinoic acid. Blood, 57(6):
1000-1004, 1981.
12.Koeffler, H. P. Induction of differentiation of human acute
myelogenous leukemia cells: therapeutic implications. Blood,
62: 709-721, 1983.
13.Lanotte, M.; Martin-Thouvenin, V.; Najman, S.; Balerini, P.;
Valensi, F.; Berger, R. NB4, a maturation inducible cell line
with t(15;17) marker isolated from a human acute
promyelocytic leukemia (M3). Blood, 77(5): 1080-1086, 1991.
14.Huang, M. E.; Ye, Y. C.; Chen, S. R.; Chai, J. R.; Lu, J.
X.; Zhoa, L.; Gu, L. J.; Wang, Z. Y. Use of all-trans
retinoic acid in the treatment of acute promyelocytic
leukemia. Blood, 72(2): 567-572, 1988.
15.Kakizuka, A.; Miller, W. H.; Umesono, K.; Warrell, R. P.;
Frankel, S. R.; Murty, V.V.V.S.; Dimitrovsky, E.; Evans, R.
M. Chromosomal translocation t(15;17) in human acute
promyelocytic leukemia fuses RAR with a novel putative
transcription factor, PML. Cell, 66: 663, 1991.
16.Carr, Jacqueline H.; Bernadette, F. Rodak. Clinical
hematology atlas. Philadelphia : Saunders, c1999.
17.Henderson, L. M.; Chappel, J. B. NADPH oxidase of
neutrophils. Biochim. Biophys. Acta. 1273(2): 87-107, 1996.
18.Norman, A. W.; Zhou, J. Y.; Henry, H. L.; Uskokovic, M. R.;
Koeffler, H. P. Structure-function studies on analogues of 1
alpha, 25- dihydroxyvitamin D3: differential effects on
leukemic cell growth, differentiation, and intestinal calcium
absorption. Cancer Res. 50(21): 6857-6864, 1990.
19.Hozumi, M. Fundamentals of Chemo-differentiation therapy of
myeloid leukemia. AntiCancer Res. 14: 1177-1192, 1994.
20.Samid, D.; Yeh, A.; Prasanna, P. Induction of erythroid
differentiation and fetal hemoglobin production in human
leukemic cells treated with phenylacetate. Blood, 80(6): 1576-
1581, 1992.
21.Jing, Y.; Waxman, S. Structural requirements for
differentiation-induction and growth-inhibition of mouse
erythroleukemia cells by isoflavones. AntiCancer Res. 15(4):
1147-1152, 1995.
22.Mizutani, Y.; Masuoka, S.; Imoto, M.; Kawada, M.; Umezawa,
K. Induction of erythroid differentiation in leukaemic K562
cells by an S-adenosylhomocysteine hydrolase inhibitor,
aristeromycin. Biochem. Biophys. Res. Commun. 207(1): 69-74,
1995.
23.Jing, Y.; Wang, L.; Xia, L.; Chen, Guo-qiang; Chen, Zhu.;
Miller, W.H.; and Waxman, S. Combined effect of all-trans
retinoic acid and arsenic trioxide in acute promyelocytic
leukemia cells in vitro and in vivo. Blood, 97: 264-269, 2001.
24.Numazawa, S.; Shinoki, M. A.; Ito, H.; Yoshida, T.; Kuroiwa,
Y. Involvement of Na+, K+-ATPase inhibition in K562 cell
differentiation induced by bufalin. J. Cell. Physiol. 160(1):
113-120, 1994.
25.Sato, S.; Tomoyasu, S.; Okabe-Kado, J.; Hozumi, M.;Tsuruoka,
N.; Nakai, S.; Adachi, M.; Honma, Y. Induction of
differentiation and enhancement of vincristine sensitivity of
human erythroleukemia HEL cells by vesnarinone, a positive
inotropic agent. Exp. Hematol. 24(1): 37-42, 1996.
26.Degos, L. All-trans retinoic acid (ATRA) therapeutical
effect in acute promyelocytic leukemia. [Review] Biomedicine
& Pharmacotherapy. 46(5-7): 201-209, 1992.
27.Castaigne, S.; Chomienne, C.; Daniel, M. T.; Ballerini, P.;
Berger, R.; Fenaux, P.; Degos, L. All-trans retinoic acid as
a differentiation therapy for acute promyelocytic leukemia.
I. Clinical results. Blood, 76(9): 1704-1709, 1990.
28.Fiorella, P. D.; Giguere, V.; Napoli, J. L. Expression of
cellular retinoic acid-binding protein (type II) in
Escherichia coli. Characterization and comparison to cellular
retinoic acid-binding protein (type I). J. Biol. Chem. 268
(29): 21545-21552, 1993.
29.Giguere, V. Retinoic acid receptors and cellular retinoid
binding proteins: complex interplay in retinoid signaling.
[Review] Endocr. Rev. 15(1): 61-79, 1994.
30.Lefebvre, P.; Thomas, G.; Gourmel, B.; Agadir, A.;
Castaigne, S.; Dreux, C.; Degos, L.; Chomienne, C.
Pharmacokinetics of oral all-trans retinoic acid in patients
with acute promyelocytic leukemia. Leukemia, 5(12): 1054-
1058, 1991.
31.Muindi, J.; Frankel, S. R.; Miller, W. H. Jr.; Jakubowski,
A.; Scheinberg, D. A.; Young, C. W.; Dmitrovsky, E.; Warrell,
R. P. Jr. Continuous treatment with all-trans retinoic acid
causes a progressive reduction in plasma drug concentrations:
implications for relapse and retinoid "resistance" in
patients with acute promyelocytic leukemia. Blood, 79(2): 299-
303, 1992.
32.Frankel, S. R.; Eardley, A.; Lauwers, G.; Weiss, M.;
Warrell, R. P. Jr. The "retinoic acid syndrome" in acute
promyelocytic leukemia. Ann. Intern. Med. 117(4): 292-296,
1992.
33.Sakurai, M.; Sampi, K.; Hozumi, M. Possible differentiation
of human acute myeloblastic leukemia cells by daily and
intermittent administration of aclacinomycin-A. Leuk.
Research. 7(2): 139-143, 1983.
34.Housset, M.; Daniel, M. T.; Degos, L. Small doses of ARA-C
in the treatment of acute myeloid leukaemia: differentiation
of myeloid leukaemia cells? British Journal of Haematology. 51
(1): 125-129, 1982.
35.Engvild, K. C. The death hormone hypothesis. Physiol Plant.;
77 282-5, 1989.
36.Folkes, L. K.; Dennis, M. F.; Stratford, M. R.; Candeias, L.
P.; Wardman, P. Peroxidase-catalyzed effects of indole-3-
acetic acid and analogues on lipid membranes, DNA, and
mammalian cells in vitro. Biochem. Pharmacol. 57(4): 375-382,
1999.
37.Folkes, L. K.; Wardman, P. Oxidative activation of indole-3-
acetic acids to cytotoxic species- a potential new role for
plant auxins in cancer therapy. Biochem. Pharmacol. 61(2):
129-136, 2001.
38.Folkes, L. K.; Candeias, L. P.; Wardman, P. Toward
targeted "oxidation therapy" of cancer: peroxidase-catalysed
cytotoxicity of indole-3-acetic acids. Int. J. Radiat. Oncol.
Biol. Phys. 42(4): 917-920, 1998.
39.Napier, M. P.; Sharma, S. K.; Springer, C. J.; Bagshawe, K.
D.; Green, A. J.; Martin, J.; Stribbling, S. M.; Cushen, N.;
O''Malley, D.; Begent, R. H. Antibody-directed enzyme prodrug
therapy: efficacy and mechanism of action in colorectal
carcinoma. Clin. Cancer Res. 6(3): 765-772, 2000.
40.Bagshawe, K. D.; Sharma, S. K.; Springer, C. J.; Rogers, G.
T. Antibody directed enzyme prodrug therapy (ADEPT). A review
of some theoretical, experimental and clinical aspects.
[Review] Ann. Oncol. 5(10): 879-891, 1994.
41.Melton, R. G.; Sherwood, R. F. Antibody-enzyme conjugates
for cancer therapy. [Review] J. Natl. Cancer Inst. 88(3-4):
153-165, 1996.
42.Draetta, G. F. Mammalian G1 cyclins. Curr. Opin. Cell Biol. 6
(6): 842-846, 1994.
43.Murray, A. W.; Solomon, M. J.; Kirschner, M. W. The role of
cyclin synthesis and degradation in the control of maturation
promoting factor activity. Nature, 339: 280, 1989.
44.Lees, E. Cyclin dependent kinase regulation. Curr. Opin.
Cell Biol. 7(6): 773-780, 1995.
45.Rodt, H.; Netzel, B.; Thiel, E.; Jager, G.; Huhn, D.; Haas,
R.;Gotze, D.; Thierfelder, S. Classification of leukemic
cells with T- and O-ALL-specific antisera. Hamatologie und
Bluttransfusion. 20: 87-96, 1977.
46.Schlossman, S. F.; Boumsell, L.; Gilks, W. Leukocyte Typing.
Vol. V: White Cell Differentiation Antigens. Oxford
University Press, Oxford, 1994.
47.Shipp, M. A.; Look, A. T. Hematopoietic differentiation
antigens that are membrane-associated enzymes: cutting is the
key ? Blood, 82: 1052-1070, 1993.
48.Terstappen, L. W.; Gandour, D.; Huang, S.; Lund-Johansen F.;
Manion, K.; Nguyen, M.; Mickaels, R.; Olweus, J.; Topker, S.
Assessment of hematopoietic cell differentiation by
multidimensional flow cytometry. Journal of Hematotherapy. 2
(3): 431-447, 1993.
49.Brown, G.; Capellaro, D.; Greaves, M.; Leukemia-associated
antigens in man. J. Natl. Cancer Inst. 55(6): 1281-1289, 1975.
50.Peter, H.; Wiernik. et. al. Neoplastic diseases of the
Blood, 3rd ed. New York : Churchill Livingstone, 1996.
Chapter 14, P218
51.Hickstein, D. D.; Back, A. L.; Collins, S. J. Regulation of
expression of the CD11b and CD18 subunits of the neutrophil
adherence receptor during human myeloid differentiation. J.
Biol. Chem. 264(36): 21812-21817, 1989.
52.Lund-Johansen F.; Terstappen, L. W. Differential surface
expression of cell adhesion molecules during granulocyte
maturation. J. Leukoc. Biol. 54(1):47-55, 1993.
53.Watanabe, M.; Shimamoto, Y.; Yoshida, S.; Suga, K.;
Mizuguchi, Y.; Kohashi, O.; Yamaguchi, M. Intracellular
multiplication of Legionella pneumophila in HL-60 cells
differentiated by 1,25-dihydroxyvitamin D3 and the effect of
interferon gamma. J. Leukoc. Biol. 54(1):40-46, 1993.
54.Gutterman, J. U. Cytokine therapeutics: lessons from
interferon alpha. [Review] Proc. Natl. Acad. Sci. USA. 91(4):
1198-1205, 1994.
55.Bokseon Bae; Susan, S. Retinoic Acid-Induced HL-60 Cell
Differentiation Is Augmented by Copper Supplementation. J.
Nutr. 123: 997-1002, 1993.
56.Makishima, M.; Kanatani, Y.; Yamamoto-Yamaguchi, Y.; Honma,
Y.Enhancement of activity of 1alpha, 25-dihydroxyvitamin D3
for growth inhibition and differentiation induction of human
myelo-monocytic leukemia cells by tretinoin tocoferil, an
alpha-Tocopherol ester of all-trans retinoic acid. Blood, 87
(8):3384-3394, 1996.
57.Lopez-Lluch, G.; Buron, M. I.; Alcain, F. J.; Quesada, J.
M.; Navas, P. Redox regulation of cAMP levels by ascorbate in
1,25-dihydroxy-vitamin D3-induced differentiation of HL-60
cells. Biochem. J. 331 ( Pt 1): 21-27, 1998.
58.He, Q.; Jiang, D.; A novel aminosteroid is active for
proliferation inhibition and differentiation induction of
human acute myeloid leukemia HL-60 cells. Leuk. Res. 23(4):
369-372, 1999.
59.Kawaii, S.; Tomono, Y.; Katase, E.; Ogawa, K.; Yano, M.; T
Takemura, Y.; Ju-ichi, M.; Ito, C.; Furukawa, H. Acridones as
inducers of HL-60 cell differentiation. Leuk. Res. 23(3):263-
269, 1999.
60.Sham, R. L.; Phatak, P. D.; Belanger, K. A.; Braggins, C.;
Packman, C. H. Functional characteristics of mature
granulocytes in a patient with acute promyelocytic leukemia
treated with all-trans retinoic acid. Leuk. Res. 19(8): 505-
511, 1995.
61.Berridge, M. V.; Tan, A. S. Characterization of the cellular
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT): subcellular localization,
substrate dependence, and involvement of mitochondrial
electron transport in MTT reduction. Arch. Biochem. Biophys.
303: 474—482, 1993.
62.Ishiyama, M.; Tominaga, H.; Shiga, M.; Sasamoto, K.; Ohkura,
Y.;Ueno, K.; Watanabe, M. Novel cell proliferation and
cytotoxicity assays using a tetrazolium salt that produces a
soluble formazan dye. In Vitro Toxicol. 8: 187—190, 1995.
63.Yoshida, K.; Murohashi, I.; Hirashima, K. p53-independent
induction of p21 (WAF1/CIP1) during differentiation of HL-60
cells by tumor necrosis factor alpha. Int. J. Hematol. 65(1):
41-48, 1996.
64.Kanatani, Y.; Makishima, M.; Ishikawa, I.; Ogasawara, Y.;
Kawahara, N.; Motoyoshi, K.; Nagata, N.; Honma, Y. A novel
uracil analog, 6-chloro-5-(2-propenyl)uracil, preferentially
enhances growth inhibition and differentiation of myeloid
leukemia cells induced by 1alpha,25- dihydroxyvitamin D3.
Exp. Hematol. 26(3): 198-206, 1998.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 19. 林錦村,論司法警察之「無證搜索」,全國律師第二卷第十一期,民國八十七年十一月。
2. 34. 黃朝義,起訴卷證不併送制度下之證據開示原則,月旦法學雜誌第五十四期,民國八十八年十一月。
3. 19. 溫武慶,急性白血病。健康世界,130:250民85.11頁89-91。
4. 43. 鄭善印,日本刑事訴訟法上警察對輕微犯罪的處理,律師雜誌第二三四期。
5. 40. 蔡墩銘,監聽與強制處分,法令月刊第四十二卷第六期,民國八十年六月。
6. 38. 楊竹生,論美國憲法第四修正案所述搜索與扣押,中原財經法學第一期民國八十四年六月。
7. 36. 黃朝義,起訴卷證不併送制度與公判庭上三面關係之合理建構,律師雜誌七月號,第二三八期。
8. 48. 嚴震生,免於無理的拘捕、搜索與扣押:美國憲法第四條修正案之探討,美歐月刊第十一卷第十期,民國八十五年十月。
9. 35. 黃朝義,警訊筆錄的證據法上問題,法學叢刊第一七一期。
10. 44. 鄭善印,我國檢警關係重要問題之研究-中日撿警關係比較,警政學報第十八期。
11. 34. 黃朝義,起訴卷證不併送制度下之證據開示原則,月旦法學雜誌第五十四期,民國八十八年十一月。
12. 43. 鄭善印,日本刑事訴訟法上警察對輕微犯罪的處理,律師雜誌第二三四期。
13. 33. 黃朝義,起訴卷證併送與法庭權責不明下實施交互詰問之省思,月旦法學雜誌第六十六期,民國八十九年十一月。
14. 40. 蔡墩銘,監聽與強制處分,法令月刊第四十二卷第六期,民國八十年六月。
15. 29. 陳樸生,刑事訴訟之證據排除與禁止(一)至(四),軍法專刊三十八卷八至十一期。
 
系統版面圖檔 系統版面圖檔